| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Sterility | 0.2 μm Filtered |
| Target | B7-H6 |
| Alternative Names | NCR3LG1, B7H6, DKFZp686O24166 |
| Clone | BI-765049 |
| Source/Isotype | Human IgG1 (REEM, L234A, L235A), Kappa |
| Application | Bioactivity-ELISA |
| Description | B7-H6 is a member of the immunoglobulin superfamily. As a ligand for NK cell receptor NKP30, it has a tumor-specific expression profile-not expressed in normal tissues, but highly expressed in a variety of tumors, is an important tumor-associated antigen. It kills tumors by activating NK cells, and promotes tumor progression through cancer-promoting signaling pathways (such as Ras/MEK/Erk) . Its expression level is related to tumor immune escape and patient prognosis. Based on this, BI-765049 antibody, as a bispecific monoclonal antibody of B7-H6/CD3, can activate T cells to directionally kill B7-h6 positive tumor cells, and provide a new immunotherapy strategy for digestive tract tumors. |
| Formulation | phosphate-buffered solution, pH 7.2-7.4. |
| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Sterility | 0.2 μm Filtered |
| Target | B7-H6 |
| Alternative Names | NCR3LG1, B7H6, DKFZp686O24166 |
| Clone | BI-765049 |
| Source/Isotype | Human IgG1 (REEM, L234A, L235A), Kappa |
| Application | Bioactivity-ELISA |
| Description | B7-H6 is a member of the immunoglobulin superfamily. As a ligand for NK cell receptor NKP30, it has a tumor-specific expression profile-not expressed in normal tissues, but highly expressed in a variety of tumors, is an important tumor-associated antigen. It kills tumors by activating NK cells, and promotes tumor progression through cancer-promoting signaling pathways (such as Ras/MEK/Erk) . Its expression level is related to tumor immune escape and patient prognosis. Based on this, BI-765049 antibody, as a bispecific monoclonal antibody of B7-H6/CD3, can activate T cells to directionally kill B7-h6 positive tumor cells, and provide a new immunotherapy strategy for digestive tract tumors. |
| Formulation | phosphate-buffered solution, pH 7.2-7.4. |
